Treating haemophilia A with recombinant blood factors: a comparison

被引：20

作者：

Ananyeva, N ^{[1
]}

Khrenov, A ^{[1
]}

Darr, F ^{[1
]}

Summers, R ^{[1
]}

Sarafanov, A ^{[1
]}

Saenko, E ^{[1
]}

机构：

[1] Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Biochem, Rockville, MD 20855 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2004年 / 5卷 / 05期

关键词：

blood-borne pathogens; efficacy; Factor VIII; FVIII concentrate consumption; haemophilia A; plasma-derived; recombinant; safety; unconstrained FVIII demand;

D O I：

10.1517/14656566.5.5.1061

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The mainstay in the treatment of haemophilia A is replacement therapy with repeated infusions of plasma-derived Factor VIII (FVIII) concentrates or recombinant FVIII products. While modern plasma-derived FVIII concentrates have an excellent safety profile, there is an inexorable shift towards the use of recombinant products, especially in affluent countries. Recombinant FVIII products have demonstrated excellent haemostatic efficacy and higher safety with regard to the transmission of blood-borne pathogens. The experience in haemophilia A treatment with five currently available recombinant FVIII products, including the first third-generation product, Advate(R), which is completely free from human or animal proteins, is summarised. Some unresolved problems concerning the efficacy and assaying of recombinant factors and future perspectives of both recombinant and plasma-derived FVIII products in global haemophilia care, are also discussed.

引用

页码：1061 / 1070

页数：10

共 80 条

[1]

Abshire TC, 2000, THROMB HAEMOSTASIS, V83, P811

[2]

ADDIEGO JE, 1992, THROMB HAEMOSTASIS, V67, P19

[3]

Auerswald G, 2003, Haematologica, V88

[4] The transfusion-associated transmission of parvovirus B19 [J].

Azzi, A ;

Morfini, M ;

Mannucci, PM .

TRANSFUSION MEDICINE REVIEWS, 1999, 13 (03) :194-204

[5] Standardization of FVIII & FIX assays [J].

Barrowcliffe, TW .

HAEMOPHILIA, 2003, 9 (04) :397-402

[6] Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations [J].

Barrowcliffe, TW ;

Raut, S ;

Sands, D ;

Hubbard, AR .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03) :247-255

[7]

Behrmann M, 2002, THROMB HAEMOSTASIS, V88, P221

[8]

Boedeker BGD, 2001, SEMIN THROMB HEMOST, V27, P385

[9] Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency [J].

Bovenschen, N ;

Herz, J ;

Grimbergen, JM ;

Lenting, PJ ;

Havekes, LM ;

Mertens, K ;

van Viijmen, BJM .

BLOOD, 2003, 101 (10) :3933-3939

[10]

BRAY GL, 1994, BLOOD, V83, P2428

← 1 2 3 4 5 6 7 8 →